|Publication Type||Journal Article|
|Year of Publication||2010|
|Authors||Kim, SY, Dunn, IF, Firestein, R, Gupta, P, Wardwell, L, Repich, K, Schinzel, AC, Wittner, B, Silver, SJ, Root, DE, Boehm, JS, Ramaswamy, S, Lander, ES, Hahn, WC|
Aberrant beta-catenin signaling plays a key role in several cancer types, notably colon, liver and breast cancer. However approaches to modulate beta-catenin activity for therapeutic purposes have proven elusive to date.